Jorma J. Isola
#137,103
Most Influential Person Now
Jorma J. Isola's AcademicInfluence.com Rankings
Jorma J. Isolabiology Degrees
Biology
#9469
World Rank
#12680
Historical Rank
Genetics
#969
World Rank
#1065
Historical Rank
Molecular Biology
#1300
World Rank
#1327
Historical Rank
Biochemistry
#1447
World Rank
#1572
Historical Rank

Download Badge
Biology
Jorma J. Isola's Degrees
- PhD Molecular Biology University of Helsinki
- Masters Biochemistry University of Helsinki
Why Is Jorma J. Isola Influential?
(Suggest an Edit or Addition)Jorma J. Isola's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- In vivo amplification of the androgen receptor gene and progression of human prostate cancer (1995) (1521)
- Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. (2006) (1138)
- Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors (1994) (1073)
- Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. (2002) (820)
- Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. (1997) (780)
- Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. (2005) (700)
- Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. (1995) (543)
- Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity (2007) (535)
- Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. (2005) (469)
- ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 (2010) (465)
- Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. (2009) (455)
- Genetic heterogeneity and clonal evolution underlying development of asynchronous metastasis in human breast cancer. (1997) (433)
- Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. (1994) (428)
- Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. (2000) (409)
- Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. (1997) (407)
- Molecular cytogenetics of primary breast cancer by CGH (1998) (398)
- Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. (2000) (391)
- Trastuzumab emtansine: mechanisms of action and drug resistance (2014) (371)
- Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. (1992) (369)
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair (2008) (369)
- Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer (1991) (361)
- Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. (1996) (351)
- Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. (2000) (347)
- Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. (1995) (331)
- Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. (1992) (328)
- Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. (1992) (323)
- Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. (1996) (314)
- Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. (1998) (314)
- HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. (2002) (290)
- Estrogen Receptor β Is Coexpressed with ERα and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer (2000) (279)
- Current Perspectives on HER2 Testing: A Review of National Testing Guidelines (2003) (278)
- Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. (2004) (257)
- Cytogenetic Alterations and Cytokeratin Expression Patterns in Breast Cancer: Integrating a New Model of Breast Differentiation into Cytogenetic Pathways of Breast Carcinogenesis (2002) (256)
- Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. (2006) (254)
- CIP2A Is Associated with Human Breast Cancer Aggressivity (2009) (237)
- Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. (2003) (222)
- Trastuzumab causes antibody-dependent cellular cytotoxicity–mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance (2007) (220)
- Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study (2011) (209)
- Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. (2001) (208)
- Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors (2005) (201)
- Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. (1996) (198)
- Risk for distant recurrence of breast cancer detected by mammography screening or other methods. (2004) (197)
- Evaluation of cell proliferation in breast carcinoma. Comparison of Ki‐67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count (1990) (193)
- Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo (2011) (190)
- Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. (2005) (187)
- Interlaboratory Comparison of HER-2 Oncogene Amplification as Detected by Chromogenic and Fluorescence in situ Hybridization (2004) (182)
- Characterization of topoisomerase IIα gene amplification and deletion in breast cancer (1999) (177)
- Amplification of KIT, PDGFRA, VEGFR2, and EGFR in Gliomas (2006) (176)
- Lumpectomy with or without postoperative radiotherapy for breast cancer with favourable prognostic features: results of a randomized study (2001) (175)
- Prognostication of astrocytoma patient survival by Ki‐67 (MIB‐1), PCNA, and S‐phase fraction using archival paraffin‐embedded samples (1994) (173)
- Genetic alterations in lobular breast cancer by comparative genomic hybridization (1997) (171)
- Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. (2002) (169)
- Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. (2003) (166)
- Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors (1993) (165)
- Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. (2004) (163)
- HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. (2011) (161)
- Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. (1998) (154)
- Low biologic aggressiveness in breast cancer in women using hormone replacement therapy. (1998) (152)
- Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. (2005) (152)
- Optimizing DOP‐PCR for universal amplification of small DNA samples in comparative genomic hybridization (1997) (151)
- Estrogen Receptor β Expression Is Associated with Tamoxifen Response in ERα-Negative Breast Carcinoma (2007) (147)
- Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. (1995) (147)
- Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma (2006) (144)
- Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. (1999) (144)
- Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. (2007) (141)
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. (2011) (141)
- Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. (1994) (140)
- Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers (2007) (140)
- Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. (2000) (137)
- Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer. (1996) (132)
- HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel (2004) (131)
- Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping (2000) (127)
- Basoluminal Carcinoma: A New Biologically and Prognostically Distinct Entity Between Basal and Luminal Breast Cancer (2006) (127)
- 3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. (2009) (124)
- ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. (2004) (120)
- Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. (2003) (118)
- Association of Wwox with ErbB4 in breast cancer. (2007) (115)
- The effect of age and density of the breast on the sensitivity of breast cancer diagnostic by mammography and ultasonography (2001) (114)
- Genetic changes in intraductal breast cancer detected by comparative genomic hybridization. (1997) (113)
- Female predominance in meningiomas can not be explained by differences in progesterone, estrogen, or androgen receptor expression (2006) (113)
- Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening (2008) (112)
- HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. (2001) (112)
- Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. (1993) (111)
- Patterns of chromosomal imbalances in parathyroid carcinomas. (2000) (110)
- Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (107)
- Colocalization of peptide and glucocorticoid receptor immunoreactivities in rat central amygdaloid nucleus. (1992) (107)
- Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer (1994) (106)
- MYB oncogene amplification in hereditary BRCA1 breast cancer. (2000) (104)
- Mechanical loading regulates tenascin-C expression in the osteotendinous junction. (1999) (104)
- Localization of the glucocorticoid receptor in testis and accessory sexual organs of male rat (1993) (104)
- Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer study (2004) (103)
- A digital atlas of breast histopathology: an application of web based virtual microscopy (2004) (102)
- Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. (2010) (101)
- Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. (2003) (101)
- Expression of epidermal growth factor receptor and ERBB2 (HER-2/Neu) oncoprotein in prostatic carcinomas. (1992) (99)
- Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. (1999) (98)
- Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. (1995) (97)
- Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. (2002) (95)
- EZH2, Ki‐67 and MCM7 are prognostic markers in prostatectomy treated patients (2008) (92)
- Immunohistochemical determination of estrogen and progesterone receptors in human breast carcinoma. Correlation with histopathology and dna flow cytometry (1990) (91)
- The calcium-binding protein S100P in normal and malignant human tissues (2008) (91)
- Aberrant p53 expression in astrocytic neoplasms of the brain: association with proliferation. (1993) (90)
- Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. (2006) (90)
- Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. (1994) (87)
- Effect of age on the survival of breast cancer patients. (1997) (87)
- Haplo-insufficiency of BRCA1 in sporadic breast cancer. (2003) (87)
- Web-based virtual microscopy in teaching and standardizing Gleason grading. (2005) (86)
- Carbonic anhydrase II. A novel biomarker for gastrointestinal stromal tumors (2010) (84)
- Overexpression of p53 and long-term survival in colon carcinoma. (1994) (84)
- Proliferating cell nuclear antigen immunohistochemistry using monoclonal antibody 19A2 and a new antigen retrieval technique has prognostic impact in archival paraffin-embedded node-negative breast cancer. (1993) (82)
- Steroid receptors and Ki‐67 reactivity in ovarian cancer and in normal ovary: Correlation with dna flow cytometry, biochemical receptor assay, and patient survival (1990) (81)
- Expression of ERα and ERβ in prostate cancer (2003) (80)
- Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer (2011) (79)
- Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas (2002) (76)
- Evaluation of HER-2/NEU Protein Expression in Breast Cancer by Immunohistochemistry: An Interlaboratory Study Assessing the Reproducibility of HER-2/NEU Testing (2002) (73)
- Genetic aberrations in hypodiploid breast cancer: frequent loss of chromosome 4 and amplification of cyclin D1 oncogene. (1998) (71)
- Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? (2003) (71)
- Genetic alterations in ERBB2-amplified breast carcinomas. (1999) (70)
- Androgen receptor gene amplification in a recurrent prostate cancer after monotherapy with the nonsteroidal potent antiandrogen Casodex (bicalutamide) with a subsequent favorable response to maximal androgen blockade. (1997) (69)
- ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry (2012) (67)
- Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer (2008) (65)
- Breast cancer outcome prediction with tumour tissue images and machine learning (2019) (65)
- Improved prognostic impact of S-phase values from paraffin-embedded breast and prostate carcinomas after correcting for nuclear slicing. (1991) (65)
- Characterization of chromosomal abnormalities in prostate cancer cell lines by spectral karyotyping (2000) (65)
- The Application of JPEG2000 in Virtual Microscopy (2009) (65)
- Elevated levels of StAR-related lipid transfer protein 3 alter cholesterol balance and adhesiveness of breast cancer cells: potential mechanisms contributing to progression of HER2-positive breast cancers. (2015) (63)
- A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy. (2009) (63)
- Aggressiveness of screen-detected breast cancers (1995) (62)
- Aurora-A gene is frequently amplified in basal-like breast cancer. (2010) (61)
- p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. (2007) (59)
- Preservation of nucleic acids and tissue morphology in paraffin-embedded clinical samples: comparison of five molecular fixatives (2013) (59)
- Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping. (2001) (59)
- Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. (2011) (58)
- Chromosomal rearrangements and oncogene amplification precede aneuploidization in the genetic evolution of breast cancer. (2001) (58)
- Down-Regulated Xanthine Oxidoreductase Is a Feature of Aggressive Breast Cancer (2005) (57)
- Characterization of a Novel Breast Carcinoma Xenograft and Cell Line Derived from a BRCA1 Germ-Line Mutation Carrier (2003) (57)
- Stromal cell cathepsin D expression and long-term survival in breast cancer. (1995) (55)
- Flow cytometric analysis of DNA ploidy and S-phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. (1991) (54)
- Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. (2002) (54)
- Long-term prognosis of breast cancer detected by mammography screening or other methods (2011) (54)
- Amplification of c-myc Oncogene by Chromogenic and Fluorescence In Situ Hybridization in Archival Breast Cancer Tissue Array Samples (2001) (53)
- Dual‐colour chromogenic in situ hybridization for testing of HER‐2 oncogene amplification in archival breast tumours (2006) (52)
- Grading of Neuroendocrine Tumors With Ki-67 Requires High-quality Assessment Practices (2012) (51)
- Exogenous sex hormone use and risk of meningioma: a population-based case–control study in Finland (2010) (51)
- Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. (1995) (51)
- Linking Whole-Slide Microscope Images with DICOM by Using JPEG2000 Interactive Protocol (2009) (50)
- Trastuzumab decreases the number of circulating and disseminated tumor cells despite trastuzumab resistance of the primary tumor. (2008) (50)
- Epithelial Syndecan-1 Expression Is Associated with Stage and Grade in Colorectal Cancer (2005) (50)
- Increased cell proliferation activity and decreased cell death are associated with the emergence of hormone‐refractory recurrent prostate cancer (1997) (49)
- Chromosomal aberrations in breast cancer: A comparison between cytogenetics and comparative genomic hybridization (1999) (47)
- Intratumor variation in cell proliferation in breast carcinoma as determined by antiproliferating cell nuclear antigen monoclonal antibody and automated image analysis. (1993) (47)
- Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation (2018) (46)
- Web-Based Virtual Microscopy for Parasitology: A Novel Tool for Education and Quality Assurance (2008) (45)
- Amplification of c-myc by Fluorescence In Situ Hybridization in a Population-Based Breast Cancer Tissue Array (2001) (45)
- Mapping the amplification of EIF3S3 in breast and prostate cancer (2000) (45)
- Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome. (2007) (43)
- Immunocytochemical localization of progesterone receptor in the chick ovary. (1987) (43)
- Associations of ErbB2, β1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines (2005) (43)
- High topoisomerase IIα expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas (2000) (43)
- Amplification of the epidermal growth factor receptor in astrocytic tumours by chromogenic in situ hybridization: association with clinicopathological features and patient survival (2006) (42)
- Detection of germline BRCA1 mutations in breast cancer patients by quantitative messenger RNA in situ hybridization. (1996) (42)
- P53 accumulation, deoxyribonucleic acid ploidy and progression of bladder cancer. (1997) (42)
- Development of progestin-specific response in the chicken oviduct. (1989) (42)
- Accumulation of genetic changes is associated with poor prognosis in grade II astrocytomas. (1997) (41)
- Comparison of three quantitation methods for PCNA immunostaining: Applicability and relation to survival in 83 astrocytic neoplasms (1993) (41)
- Immunocytochemical detection of estrogen and progesterone receptors in 124 human breast cancers. (1988) (40)
- CDKN2/p16 Predicts Survival in Oligodendrogliomas: Comparison with Astrocytomas (1999) (40)
- Morphology and histochemistry of the myotendineal junction of the rat calf muscles. Histochemical, immunohistochemical and electron-microscopic study. (1991) (39)
- Expression of C-KIT and HER-2 tyrosine kinase receptors in poor-prognosis breast cancer. (2002) (39)
- Chromosome arm‐specific multicolor FISH (2001) (39)
- A Novel Anti-HER2 Antibody–Drug Conjugate XMT-1522 for HER2-Positive Breast and Gastric Cancers Resistant to Trastuzumab Emtansine (2019) (39)
- Virtual microscopy (2004) (38)
- Cancer incidence in families with multiple glioma patients (2002) (38)
- Overall and worst gleason scores are equally good predictors of prostate cancer progression (2011) (38)
- Expression of ERalpha and ERbeta in prostate cancer. (2003) (38)
- Molecular cytogenetics of human breast cancer. (1994) (38)
- The visibility of cancer on earlier mammograms in a population-based screening programme. (1999) (37)
- A web-based system for individualised survival estimation in breast cancer (2003) (36)
- Free digital image analysis software helps to resolve equivocal scores in HER2 immunohistochemistry (2016) (36)
- Multiple copies of mutant BRCA1 and BRCA2 alleles in breast tumors from germ‐line mutation carriers (2000) (35)
- Prognostic variables in predicting pregnancy. A prospective follow up study of 907 couples with an infertility problem. (1994) (35)
- Germline BRCA1 and HMLH1 mutations in a family with male and female breast carcinoma (2000) (35)
- Atrophy and regeneration of rat calf muscles cause reversible changes in the number of nucleolar organizer regions. Evidence that also in nonproliferating cells the number of NORs is a marker of protein synthesis activity. (1993) (34)
- Chemical castration and anti‐androgens induce differential gene expression in prostate cancer (2012) (34)
- Vitamin D Receptor Alleles and Bone's Response to Physical Activity (1998) (33)
- Genetic aberrations in pediatric acute lymphoblastic leukemia by comparative genomic hybridization. (1997) (32)
- HER-2 positive breast cancer: decreasing proportion but stable incidence in Finnish population from 1982 to 2005 (2009) (32)
- The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. (2013) (31)
- Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry (2016) (31)
- Analysis of p53 Tumor Suppressor Gene in Families with Multiple Glioma Patients (2001) (31)
- Deep learning identifies morphological features in breast cancer predictive of cancer ERBB2 status and trastuzumab treatment efficacy (2021) (31)
- Virtual microscopy in prostate histopathology: simultaneous viewing of biopsies stained sequentially with hematoxylin and eosin, and alpha-methylacyl-coenzyme A racemase/p63 immunohistochemistry. (2006) (31)
- Chromosomal translocations involving 11q13 contribute to cyclin D1 overexpression in squamous cell carcinoma of the head and neck. (2002) (31)
- Absence of polysialylated NCAM is an unfavorable prognostic phenotype for advanced stage neuroblastoma (2009) (30)
- Automated peak detection and cell cycle analysis of flow cytometric DNA histograms. (1994) (30)
- ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer. (2020) (29)
- Very high quantitative tumor HER2 content and outcome in early breast cancer. (2011) (29)
- A public-domain image processing tool for automated quantification of fluorescence in situ hybridisation signals (2007) (29)
- Frequent Amplification of Chromosomal Region 20 q 12-q 13 in Ovarian Cancer 1 (2000) (29)
- Distribution of estrogen and progesterone receptors and steroid-regulated gene products in the chick oviduct (1990) (29)
- c-erbB-2 in astrocytomas: infrequent overexpression by immunohistochemistry and absence of gene amplification by fluorescence in situ hybridization. (1996) (28)
- Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas (2005) (28)
- An immunocytochemical study of the progesterone receptor in rabbit ovary (1988) (28)
- Sources of variation in the assessment of cell proliferation using proliferating cell nuclear antigen immunohistochemistry. (1994) (27)
- Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study (2012) (27)
- Cytokeratin-Supervised Deep Learning for Automatic Recognition of Epithelial Cells in Breast Cancers Stained for ER, PR, and Ki-67 (2020) (27)
- Hormone replacement therapy and biological aggressiveness of breast cancer (1997) (26)
- Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. (2009) (25)
- Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma (2014) (25)
- Optimized JPEG 2000 Compression for Efficient Storage of Histopathological Whole-Slide Images (2018) (24)
- Chromogenic in situ hybridization-detected hotspot MYCN amplification associates with Ki-67 expression and inversely with nestin expression in neuroblastomas (2005) (24)
- Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. (2009) (24)
- Progesterone receptor in the chick bursa of fabricius: characterization and immunohistochemical localization. (1985) (24)
- Generalisability of survival estimates for patients with breast cancer--a comparison across two population-based series. (2006) (24)
- Cytogenetic characterization and gene expression profiling of the trastuzumab-resistant breast cancer cell line JIMT-1. (2007) (24)
- Chromogenic in situ hybridization in tumor pathology. (2004) (24)
- Immunoelectron-microscopic localization of a proliferation-associated antigen Ki-67 in MCF-7 cells (1990) (23)
- Characterization of Non-Specific Cytotoxic Cell Receptor Protein 1: A New Member of the Lectin-Type Subfamily of F-Box Proteins (2011) (23)
- Allelic imbalance of HER2 variant in sporadic breast and ovarian cancer. (2006) (23)
- Colocalization of Fos‐ and Glucocorticoid Receptor‐Like Immunoreactivities in the Rat Amygdaloid Complex After Immobilization Stress (1992) (23)
- L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer (2016) (22)
- Amplification and overexpression of the ABCC3 (MRP3) gene in primary breast cancer (2012) (22)
- Macromolecular composition of the myotendinous junction. (1991) (22)
- Prognostic effect of timing of operation in relation to menstrual phase of breast cancer patient--fact or fallacy. (1995) (22)
- Amplification of erbB 2 and erbB 2 Expression Are Superior to Estrogen Receptor Status As Risk Factors for Distant Recurrence in pT 1 N 0 M 0 Breast Cancer : A Nationwide Population-based Study 1 (2003) (22)
- Cyclin E amplification, over-expression, and relapse-free survival in HER-2-positive primary breast cancer (2016) (22)
- New prognostic factors in prostatic carcinoma. (1993) (21)
- A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2010) (21)
- A quality assurance exercise to evaluate the accuracy and reproducibility of chromogenic in situ hybridisation for HER2 analysis in breast cancer (2007) (21)
- Proliferative activity and steroid receptors determined by immunohistochemistry in adjacent frozen sections of 102 breast carcinomas. (1989) (21)
- Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines. (2005) (19)
- Application of bioinformatics in probe design enables detection of enteroviruses on different taxonomic levels by advanced in situ hybridization technology. (2015) (19)
- The visibility of cancer on previous mammograms in retrospective review. (2001) (19)
- Four‐color CGH: A new method for quality control of comparative genomic hybridization (1999) (19)
- Immunoelectron microscopic localization of progesterone receptor in the chick oviduct. (1987) (17)
- Histopathological variables and biomarkers enhancer of zeste homologue 2, Ki‐67 and minichromosome maintenance protein 7 as prognosticators in primarily endocrine‐treated prostate cancer (2011) (17)
- Discordant results between radioligand and immunohistochemical assays for steroid receptors in breast carcinoma. (1990) (16)
- Effect of radiotherapy on the interpretation of routine follow-up mammography after conservative breast surgery: a randomized study. (1998) (16)
- Frequent somatic loss of BRCA1 in breast tumours from BRCA2 germ-line mutation carriers and vice versa (2001) (16)
- Characterization of 10 vulvar carcinoma cell lines by karyotyping, comparative genomic hybridization and flow cytometry. (2004) (15)
- Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer. (2010) (15)
- Simultaneous localization of calcitonin gene-related peptide and neurotensin in rat central amygdaloid nucleus (1990) (15)
- Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry (2016) (14)
- Short Communication Estrogen Receptor b Is Coexpressed with ERa and PR and Associated with Nodal Status, Grade, and Proliferation Rate in Breast Cancer (2000) (13)
- Chromosome 17 polysomy: a unifying hypothesis underlying benefit from adjuvant anthracyclines (2009) (13)
- Serous and mucinous borderline tumors of the ovary: a clinicopathologic and DNA‐ploidy study of 102 cases (1996) (13)
- Immunochemical characterization of a novel mitochondrially located protein encoded by a nuclear gene within the DFNB8/10 critical region on 21q22.3. (1997) (13)
- Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer. (2001) (12)
- Validity of radiological examinations of patients with breast cancer in different age groups in a population based study. (2001) (12)
- L1 Cell Adhesion Molecule as a Predictor of Disease-Specific Survival and Patterns of Relapse in Endometrial Cancer. (2016) (12)
- Sexual maturation-associated and estrogen-induced progesterone receptor expression in the bursa of Fabricius. (1987) (12)
- Characterization of the estrogen-sensitive cells expressing progesterone receptor in the bursa of Fabricius (1987) (11)
- Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer (2018) (11)
- Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours (2006) (11)
- Inhibition of epithelial growth factor receptor signalling does not preserve epithelial barrier function after in vitro gliadin insult (2009) (11)
- Anti-oestrogen stimulation of ERBB2 ectodomain shedding from BT-474 human breast cancer cells with ERBB2 gene amplification. (1996) (11)
- No GIST-type c-kit gain of function mutations in neuroblastic tumours (2005) (10)
- Biological aggressiveness of prostate cancer in the Finnish screening trial (2009) (10)
- Quantification of Estrogen Receptor-Alpha Expression in Human Breast Carcinomas With a Miniaturized, Low-Cost Digital Microscope: A Comparison with a High-End Whole Slide-Scanner (2015) (10)
- Prognostic value of cells with more than 5c DNA content in node-negative breast cancer as determined by image cytometry from tissue sections. (1993) (10)
- Augmentation of progesterone receptor concentration by progesterone and estrogen treatments in the chick oviduct. (1984) (9)
- Imprint cytology in immunocytochemical analysis of oestrogen and progesterone receptors of breast carcinoma. (1989) (9)
- Glucocorticoid receptor‐mediated transcriptional activation of S100P gene coding for cancer‐related calcium‐binding protein (2011) (9)
- Immunocytochemical detection of progesterone receptor in breast carcinoma. Comparison of two monoclonal antibodies. (1990) (9)
- Evaluation of camera requirements for comparative genomic hybridization. (1996) (9)
- Direct Eye Visualization of Cy5 Fluorescence for Immunocytochemistry and In Situ Hybridization (2000) (8)
- Accumulation of p53 protein correlates with tumour proliferative activity in EBV positive Burkitt's lymphoma (1992) (8)
- Advances in Brief Prognostic Significance of Elevated Cyclooxygenase-2 Expression in Breast Cancer 1 (2002) (8)
- Quantitative Analysis of &ggr;-H2AX and p53 Nuclear Expression Levels in Ovarian and Fallopian Tube Epithelium from Risk-reducing Salpingo-Oophorectomies in BRCA1 and BRCA2 Mutation Carriers (2014) (7)
- S24 Update of the FINHER trial based on 5 years of follow-up (2009) (7)
- Association of Wwox with ErbB 4 in Breast Cancer (2007) (7)
- Arm-specific multicolor fluorescence in situ hybridization reveals widespread chromosomal instability in glioma cell lines. (2003) (7)
- Monoclonal-antibody-based noncompetitive avidin-biotin assay for lutropin in urine. (1988) (7)
- High cell proliferation activity determined by DNA flow cytometry predicts poor prognosis after relapse in prostate cancer. (1994) (6)
- The effect of progesterone on the localization of progesterone receptors in the nuclei of chick oviduct cells (1987) (6)
- Length of prostate biopsies is not necessarily compromised by pooling multiple cores in one paraffin block: an observational study (2015) (6)
- Routine dual-color immunostaining with a 3-antibody cocktail improves the detection of small cancers in prostate needle biopsies. (2011) (6)
- Evaluation of a web-based system for survival estimation in breast cancer (2003) (6)
- Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER 2 Gene Status in Breast Cancer (2009) (6)
- Estrogen Receptor B Expression Is Associated withTamoxifen Response in ERA-Negative Breast Carcinoma (2007) (5)
- Cryopreserved chronic lymphocytic leukemia cells analyzed by multicolor fluorescence in situ hybridization after optimized mitogen stimulation (2002) (5)
- Oestrogen receptor content and cancer cell/stroma ratio in mammary carcinoma (1988) (4)
- Immunohistochemical versus biochemical estrogen-receptor and progesterone-receptor analysis: correlation with histological parameters (2004) (4)
- Comparison of Antibodies for Immunohistochemistry-based Detection of HER3 in Breast Cancer (2016) (4)
- Microarray analysis of differentially expressed genes in ovarian and fallopian tube epithelium from risk‐reducing salpingo‐oophorectomies (2015) (4)
- Validation of a web-based prognostic system for breast cancer (2004) (4)
- A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer. (2009) (4)
- Computer-assisted image analysis of histopathological breast cancer images using step-DTOCS (2014) (3)
- [Targeted cytotoxic drugs emerging for cancer therapy]. (2011) (3)
- Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis (2021) (3)
- Correction: Web-Based Virtual Microscopy for Parasitology: A Novel Tool for Education and Quality Assurance (2008) (3)
- p-53 gene mutations as a predictive marker in advanced breast cancer patients randomly treated either with doxorubicin or with docetaxel (2004) (3)
- Ultrastructure and collagen composition of the myo-fascial junction in rat calf muscles. (1992) (3)
- Nuclear origin of progesterone receptor of the chick oviduct cytosol (2004) (3)
- 14th European Congress on Digital Pathology (2019) (3)
- 14th European Congress on Digital Pathology (2019) (3)
- 14th European Congress on Digital Pathology (2019) (3)
- Correlation of quantitative total HER2 expression and HER2 homodimers with histopathologic characteristics of breast cancers in the FinHer study. (2009) (3)
- Fluoro-Chromogenic Labelling for Detection of MCM2 to Assess Proliferation Activity in HER2-amplified Breast Carcinomas (2018) (2)
- Amplification of 20q13 locus in breast cancer: -Defining the minimal region (1994) (2)
- Quantitative measurements of HER2 expression and HER2 homodimer using a novel proximity based assay: comparison with HER2 status by immunohistochemistry and chromogenic in situ hybridization in the FinHer study. (2009) (2)
- Molecular Cytogenetics of Solid Tumor Progression (1996) (2)
- Abstract 869: PTEN/PI3K oncogenic pathway profiling informs an in vivo synergistic therapeutic model for basal-like breast cancer. (2013) (2)
- Abstract PD10-06: CXCL13 mRNA predicts Docetaxel benefit in Triple Negative tumors (2012) (2)
- Immunohistochemical determination of estrogen and progesterone receptors and DNA flow cytometry in endometrial cancer (1993) (2)
- Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401. (2005) (2)
- Influence of endocrine status on biochemical and immunocytochemical estrogen and progesterone receptor assays in breast cancer patients (1988) (2)
- Abstract P1-08-06: Low tumor CD68 mRNA content (intratumoral macrophages) is predictive for benefit from adjuvant trastuzumab in HER2-positive breast cancer: An analysis of the FinHER trial (2013) (2)
- Immunocytochemical detection of progesterone receptors in human breast cancer: correlation with steroid-binding assay and histologic parameters (1988) (2)
- Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4-1 and NRDP1, in primary breast cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis (2018) (2)
- Advances in Brief MYB Oncogene Amplification in Hereditary BRCA 1 Breast Cancer 1 (2000) (2)
- PDK 1 potentiates upstream lesions on the PI 3 K pathway in breast carcinoma (2009) (2)
- 527 POSTER Breast cancer detection in mammography screening has independent influence on survival when cancer size and biological subtype are accounted for (2007) (2)
- [Clinical pathology on the verge of virtual microscopy]. (2015) (1)
- 831 DIFFERENCES IN GENE EXPRESSION INDUCED BY CHEMICAL CASTRATION AND ANTI-ANDROGENS IN PROSTATE CANCER (2011) (1)
- Relative harms and merits of postoperative radiation following conservative surgery for low risk breast cancer (2002) (1)
- Generalizability of survival estimates for patients with breast cancer — a comparison across two population-based series (2006) (1)
- Computer program for correction of nonspecific binding in assays of steroid hormone receptors. (1988) (1)
- Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer: a prospective observational study (2012) (1)
- Clinicopathological and prognostic correlations of HER 3 expression and its degradation regulators , NEDD 4 – 1 and NRDP 1 , in primary breast cancer (2018) (1)
- Morphological extraction of cancerous nucleus in the diagnostics of breast cancer (2015) (1)
- Outcome and biomarker supervised deep learning for survival prediction in two multicenter breast cancer series (2022) (1)
- Trastuzumab emtansine: mechanisms of action and drug resistance (2014) (1)
- 449 A New method for elimination of nonspesific binding in steroid receptor assays (1983) (0)
- P04.78 Ultrarapid FGFR3 immunostaining for diagnosis of gliomas harboring FGFR3 gene fusions (2018) (0)
- Nuclei Malignancy Analysis Based on an Adaptive Bottom-Hat Filter (2016) (0)
- Hematoxylin Counterstain To Simplify Whole Slide Scanning Of Immunofluorescence Stains (2016) (0)
- Genetic Alterations in ERBB 2-amplified Breast Carcinomas 1 , 2 (1999) (0)
- Extent of 20Q13 amplicons in primary breast cancer and association with indicators of poor prognosis (1995) (0)
- Development and evaluation of an automated, Web-based tool for quantitative assessment of fluorescence in situ hybridization (2007) (0)
- Abstract 673: Exploration of tissue morphologies in breast cancer samples using unsupervised machine learning (2017) (0)
- Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer (2018) (0)
- Comparative genomic hybridization: Methodology and application in the analysis of genetic aberrations in human solid tumors (1994) (0)
- Contents Vol. 68, 2005 (2005) (0)
- Electron microscopic immunocytochemistry using the pre-embedding method (1990) (0)
- ' s response to reviews Title : Analysis of and prognostic information from disseminated tumour cells in bone marrow in primary breast cancer : a prospective observational study (2012) (0)
- Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation (2018) (0)
- Optimal Image Data Compression For Whole Slide Images (2016) (0)
- Original Article The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues (2013) (0)
- E-Cadherin Expression Breast (2015) (0)
- Growth of Breast Cancer Cells Regulated − Cleavable ErbB 4 Isoform in Estrogen Receptor (2005) (0)
- Methodological development of fluorescence in situ hybridization (1994) (0)
- Koivisto, P. et al. Analysis of genetic changes underlying local recurrence of prostate carcinoma during androgen deprivation therapy. Am. J. Pathol. 147, 1608-1614 (1996) (0)
- 7 Further studies with polyclonal antibodies against the chick oviduct progesterone receptor (1985) (0)
- Decreased CDKN2 expression in astrocytomas and oligodendrogliomas is associated with poor prognosis (1999) (0)
- Evaluation of HER-2 protein expression in primary breast cancer (PBC) by immunohistochemistry (IHC): An interlaboratory study assessing the reproducibility of HER-2 testing (2001) (0)
- Genome-wide survey of gains and losses of DNA sequences in primary prostate cancer by comparative genomic hybridization (1994) (0)
- Analyzing Toposimerase II-α and HER-2/neu co-amplification seems to be of limited value in epithelial ovarian cancer (2009) (0)
- 64 The prognostic and predictive role of HER-2 and topoisomerase II alpha in breast cancer (BC) (2003) (0)
- Trastuzumab insensitivity despite HER-2 receptor down-regulation and internalization in a novel cell line established from a Herceptinresistant breast cancer patient. (2003) (0)
- Abstract P5-02-01: Comparison of ESR1, PGR, HER2 and KI67 expression by central IHC and MammaTyper® RT-qPCR kit in the FinHer trial (2015) (0)
- P2-12-04: RACGAP1 mRNA Assay Outperforms Ki-67 as a Proliferation Marker in the FinHer Study Cohort. (2011) (0)
- [New studies on breast cancer to predict disease outcome and clinical use of these new tests]. (1991) (0)
- Digital image analysis of the tissue surface areas of site-designated and bilaterally pooled prostate biopsies. (2018) (0)
- Breast Cancer Patients with Very High Tumor HER2 Expression Levels Might Not Benefit from Treatment with Trastzumab Plus Chemotherapy: A Retrospective Exploratory Analysis of the FinHer Trial. (2009) (0)
- Optimizing Optical And Digital Resolution For Brightfield Whole Slide Scanning (2016) (0)
- Genetic basis of human prostate cancer development and progression (1995) (0)
- P1-11 Multispectral imaging for multicolor immunohistochemical and transmission in-situ hybridization (2002) (0)
- Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer (2016) (0)
- Erratum to “Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma” [Gynecol Oncol. 120 (2011) 11–17] (2012) (0)
- Estrogen and Anti-Estrogen Regulation of Amplified erbB2 Gene Expression in Human Breast Cancer Cells (1996) (0)
- Serous and mucinous borderline tumors of the ovary: a clinicopathologic and DNA-ploidy study of 102 cases (1996) (0)
- 91047154 Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: Correlation with DNA flow cytometry, biochemical receptor assay, and patient survival (1991) (0)
- [Determination of steroid receptors in breast cancer by immunohisto- chemical technics]. (1988) (0)
- 1471: Biological Aggressiveness of Prostate Cancer in the Finnish Screening Trial (2006) (0)
- Epidermal Growth Factor Receptor (EGFR) in primary breast cancer-protein expression, but not gene copy number, gives important prognostic information in tamoxifen treated patients (2008) (0)
- MASTL is enriched in cancerous and pluripotent stem cells and influences OCT1/OCT4 levels (2022) (0)
- P1-07-01: Comparison of Four HER2 Testing Methods in the Detection of HER2−Positive Breast Cancer: Results from the FinHer Study Cohort. (2011) (0)
- Estrogen receptor analysis on breast cancer imprints (1998) (0)
- Changes in importance of items in the social and personal life of breast cancer patients over time (1999) (0)
- Subject Index Vol. 68, 2005 (2005) (0)
- and Metastatic Breast Cancer in Primary α Amplification of HER-2/neu and Topoisomerase II (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jorma J. Isola?
Jorma J. Isola is affiliated with the following schools: